Genetic evidence implicating multiple genes in the MET receptor tyrosine kinase pathway in autism spectrum disorder.
A functional promoter variant of the gene encoding the MET receptor tyrosine kinase alters SP1 and SUB1 transcription factor binding, and is associated with autism spectrum disorder (ASD). Recent analyses of postmortem cerebral cortex from ASD patients revealed altered expression of MET protein and three transcripts encoding proteins that regulate MET signaling, hepatocyte growth factor (HGF), urokinase plasminogen activator receptor (PLAUR) and plasminogen activator inhibitor-1 (SERPINE1). To address potential risk conferred by multiple genes in the MET signaling pathway, we screened all exons and 5' promoter regions for variants in the five genes encoding proteins that regulate MET expression and activity. Identified variants were genotyped in 664 families (2,712 individuals including 1,228 with ASD) and 312 unrelated controls. Replicating our initial findings, family-based association test (FBAT) analyses demonstrated that the MET promoter variant rs1858830 C allele was associated with ASD in 101 new families (P=0.033). Two other genes in the MET signaling pathway also may confer risk. A haplotype of the SERPINE1 gene exhibited significant association. In addition, the PLAUR promoter variant rs344781 T allele was associated with ASD by both FBAT (P=0.006) and case-control analyses (P=0.007). The PLAUR promoter rs344781 relative risk was 1.93 (95% confidence interval [CI]: 1.12-3.31) for genotype TT and 2.42 (95% CI: 1.38-4.25) for genotype CT compared to genotype CC. Gene-gene interaction analyses suggested a significant interaction between MET and PLAUR. These data further support our hypothesis that genetic susceptibility impacting multiple components of the MET signaling pathway contributes to ASD risk.
Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, USA. daniel.campbell@vanderbilt.edu
Daniel B
DB
Campbell
Chun
C
Li
James S
JS
Sutcliffe
Antonio M
AM
Persico
Pat
P
Levitt
D000483:Alleles; D001321:Autistic Disorder / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005838:Genotype; D017228:Hepatocyte Growth Factor / Q000235:genetics; D006801:Humans; D015810:Linkage Disequilibrium; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D019859:Proto-Oncogene Proteins c-met; D017978:Receptors, Growth Factor / Q000235:genetics*; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics; D015398:Signal Transduction / Q000502:physiology
C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D011518:Proto-Oncogene Proteins; D017978:Receptors, Growth Factor; D055293:Receptors, Urokinase Plasminogen Activator; C051321:SERPINE1 protein, human; D017228:Hepatocyte Growth Factor; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met